Press releases

18 February, 2015

Regulatory

NeuroVive: Year-End Report 1 Jan. 2014 till 31 Dec. 2014

Fourth Quarter (1 Oct. 2014 - 31 Dec. 2014) · Net revenues were SEK 0 (0) and other operating income was SEK 8,000 (12,000). · Loss before tax was SEK -17,346,000 (9,169,000). · Earnings per share* we ...

11 February, 2015

Regulatory

New subsidiary secures funding of just over USD 3 m ahead of potential IPO in Taiwan

NeuroVive has established a subsidiary in Taiwan, NeuroVive Pharmaceutical Asia, Inc., which has secured initial funding totaling USD 3,255 m. The funding is sourced from Taiwanese investors, collabor ...

5 February, 2015

Regulatory

OnCore Biopharma and Tekmira Pharmaceuticals files for merger – releases further details about license agreement with NeuroVive

NeuroVive Pharmaceutial AB, a leading mitochondrial medicine company, is able to present further details regarding the previously communicated exclusive, worldwide licensing agreement with OnCore Biop ...

19 January, 2015

Regulatory

Merger between OnCore and Tekmira includes development of NVP018 for the treatment of Hepatitis B

US biotechnology company OnCore Biopharma, Inc. (OnCore), which has licensed NeuroVive's drug candidate NVP018 for the treatment of chronic Hepatitis B virus infection (HBV), has agreed to merge with ...

12 January, 2015

Regulatory

Annual General Meeting brought forward to March 30 2015

The Board of NeuroVive Pharmaceutical AB (publ) has decided to bring forward the Annual General Meeting 2015 to Monday 30 March, 2015, at 4 p.m. at Medicon Village, Scheelevägen 2, in Lund, Sweden to ...

8 December, 2014

Regulatory

NeuroVive employs a Clinical Trial Manager

NeuroVive Pharmaceutical AB (publ) has recruited Gunilla Lindgren to the position as Clinical Trial Manager. The recruitment enables NeuroVive to ensure the sustained high quality and efficient operat ...

2 December, 2014

Regulatory

NeuroVive and Skåne University Hospital initiate collaboration on clinical phase II study on kidney protection during heart surgery

NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, has initiated a collaboration with Skåne University Hospital to complete a clinical phase II study on the evaluation of the comp ...

19 November, 2014

Regulatory

NeuroVive: Interim Report 1 Jan. 2014 to 30 Sep. 2014

Important outlicensing deal and increased focus on core operations

29 October, 2014

Regulatory

Annual General Meeting 2015 and information about members appointed to the Nomination Committee

The Annual General Meeting in NeuroVive Pharmaceutical AB (publ) will be held on Wednesday 29 April, 2015, at 4 p.m. at Medicon Village, Scheelevägen 2, in Lund, Sweden.

11 September, 2014

Addendum: OnCore License

At the request of NASDAQ OMX Stockholm, the Company provides the following information regarding the license agreement referred to in the press release dated September 9, 2014.

9 September, 2014

Regulatory

NeuroVive signs USD 150 m agreement with OnCore BioPharma for the outlicensing of NVP018 for the treatment of chronic Hepatitis B virus infection

NeuroVive Pharmaceutial AB, a leading mitochondrial medicine company, has signed an exclusive global outlicensing agreement with the US biotechnology company OnCore BioPharma, Inc. related to the deve ...

20 August, 2014

Regulatory

NeuroVive: Interim Report 1 Jan. 2014 to 30 Jun. 2014

NeuroVive's research wins award at international research symposium